Rare disease drugmaker · based in Copenhagen, Denmark · founded 2007 · ticker ASND · ascendispharma.com
Ascendis Pharma A/S works on 3 rare diseases we track, including Achondroplasia, Hypoparathyroidism and 1 more. It has 10 active clinical trials, and 7 are looking for volunteers now. It also has 3 FDA-approved rare disease drugs.
Ascendis Pharma is a biopharmaceutical company applying its TransCon technology platform to develop long-acting prodrug therapies for rare endocrine diseases. The company markets Skytrofa for growth hormone deficiency in children and adults, Yorvipath for hypoparathyroidism in adults, and Yuviwel for children with achondroplasia aged 2 and older.
Ascendis Pharma A/S pipeline
Each row lists the diseases Ascendis Pharma A/S is studying at that stage, from the ones closest to approval down to the earliest work.
These are Ascendis Pharma A/S trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.
7 trials looking for volunteers now
Looking for volunteersPhase 3Recently updatedNCT07081997
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
TestsPalopegteriparatide Experimental Arm, Palopegteriparatide Control Arm
For Hypoparathyroidism, Endocrine System Diseases and Parathyroid Diseases
This trial has a treatment duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.
Looking for volunteersPhase 3Recently updatedNCT07221851
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
For Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature and Small for Gestational Age at Delivery
This basket trial will enroll prepubertal children and adolescents with clinically diagnosed and genetically confirmed (if applicable) TS, SHOX-D, SGA, or ISS between ages of ≥2 and \<18 years with open growth plates. The purpose of the study is to see how well treatment with once-weekly lonapegsomatropin works compared to treatment with daily somatropin. Approximately 186 participants will be distributed equally (1:1), to receive either lonapegsomatropin for 2 years or somatropin for 1 year followed by lonapegsomatropin for 1 year. This trial will be conducted in the United States, France, Germany, Italy, Romania, Spain and South Korea.
Chronichypoparathyroidism is a rare condition in which the parathyroid glands do not make enough parathyroid hormone (PTH). PTH helps control the levels of calcium and phosphate in the blood. When there is not enough PTH, calcium levels can become too low and phosphate levels can become too high. This may cause symptoms such as tingling, muscle cramps, weakness, or other health problems.
The most common cause of chronichypoparathyroidism is surgery in the neck area. It can happen after thyroid surgery, surgery on the parathyroid glands, or other operations in the neck.
At the moment, most patients are treated with calcium and vitamin D tablets. These treatments help control calcium levels, but they cannot fully replace the normal effects of PTH in the body. A medicine that contains a form of human PTH is available for some patients, but it is not yet the standard treatment for everyone.
This registry collects medical information and follows patients over time. Its aim is to better understand patients' symptoms, possible long-term health problems, treatments, and overall health. A group of patients who have had their thyroid removed but do not have hypoparathyroidism will also be included for comparison.
This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed their infant(s). The potential transfer of palopegteriparatide into breast milk will be assessed.
This trial will enroll adolescents between ages of ≥12 and \<18 years with clinically diagnosed hypoparathyroidism . The purpose of the study is to see how well treatment with once-daily palopegteriparatide works and how safe it is. At least 12 participants will receive palopegteriparatide for 234 weeks. This trial will be conducted in Europe.
This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in infants with genetically verified heterozygous ACH, aged 0 to \< 2 years at the time of randomization.
Looking for volunteersNo updates in a whileNCT07345494
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.
The purpose of this clinical trial is to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of navepegritide 100 μg/kg compared to placebo (inactive drug) in adolescents aged 12 to 18 years with Achondroplasia. What will be measured is Annualized Growth Velocity after a 52-week treatment period.
Follow a condition Ascendis Pharma A/S is studying
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Ascendis Pharma A/S. Unsubscribe anytime.
You'll get, for Achondroplasia:
Trial Alerts, when a new trial opens or a trial changes
Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
As a rare disease specialist, Ascendis Pharma A/S has active clinical trial programs and drug development efforts across 3 rare diseases, including Achondroplasia, Hypoparathyroidism, Turner Syndrome. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows active and recruiting rare disease studies sponsored by Ascendis Pharma A/S, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites.
The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Ascendis Pharma A/S is headquartered in Copenhagen, Denmark, founded in 2007, publicly traded under the ticker symbol ASND. The company focuses its research and development mainly on rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Where Ascendis Pharma A/S trials take place
The trials above run at 117 study sites in 19 countries. Tap a country to see its states, cities and hospitals.
United States
61▼
France
9▼
Germany
7▼
South Korea
7▼
Italy
6▼
Spain
6▼
Denmark
3▼
Ireland
3▼
United Kingdom
3▼
Romania
2▼
Canada
2▼
Poland
1▼
Rare diseases Ascendis Pharma A/S works on
Each disease page lists every open trial, not only Ascendis Pharma A/S's, plus approved treatments.
Achondroplasia is the most common form of short-limbed dwarfism, caused by a mutation in the FGFR3 gene that disrupts the conversion of cartilage to bone in the growth plates.
How common: Approximately 1 in 25,000 live births; estimated 25,000 to 30,000 people in the United States
Hypoparathyroidism is an endocrine disorder caused by insufficient production of parathyroid hormone (PTH), resulting in chronically low calcium and elevated phosphorus levels in the blood.
How common: Approximately 22 per 100,000 for postsurgical forms; estimated 70,000 to 77,000 people living with chronichypoparathyroidism in the United States
Turner syndrome results from complete or partial absence of an X chromosome in females, causing short stature, gonadal dysgenesis, cardiac and renal abnormalities.
How common: 1 in 2,000 to 3,000 live female births
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Ascendis Pharma A/S's own site is ascendispharma.com, and our help paying for treatment page lists drugmaker programs and charity funds.
Ascendis Pharma is a biopharmaceutical company applying its TransCon technology platform to develop long-acting prodrug therapies for rare endocrine diseases. The company markets Skytrofa for growth hormone deficiency in children and adults, Yorvipath for hypoparathyroidism in adults, and Yuviwel for children with achondroplasia aged 2 and older.
Ascendis Pharma A/S has active programs across 3 rare diseases: Achondroplasia, Hypoparathyroidism, Turner Syndrome. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.
Yes, mainly. Ascendis Pharma A/S is a rare disease specialist headquartered in Copenhagen, Denmark, founded in 2007. The company focuses primarily on developing treatments for rare and orphan diseases, with programs targeting Achondroplasia, Hypoparathyroidism, Turner Syndrome.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Ascendis Pharma A/S, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
Ascendis Pharma A/S has 2 FDA-approved drugs with a rare disease use that we track, as of November 2026.
Source: the FDA's openFDA label database, matched to the rare diseases on Trial Friend; the list updates automatically and can include older products.
Yes, for 2 of its FDA-approved rare disease medicines that we track, each checked on Ascendis Pharma A/S' own website.
Yuviwel: Ascendis Signature Access Program (A.S.A.P), 1-844-442-7236. Offers copay help with private insurance, a free medicine program and insurance help. Checked September 29, 2026.
Yorvipath: Ascendis Signature Access Program (A·S·A·P), 1-844-442-7236. Offers copay help with private insurance, a free medicine program and insurance help. Checked October 12, 2026.
Medicare and Medicaid: drugmaker copay cards are limited to private insurance, so people with government coverage usually look to a free medicine program or a charity fund, both on the help paying page.
Eligibility is decided by each program, so call the number listed before a prescription is filled.
Ascendis Pharma A/S was founded in 2007 and is headquartered in Copenhagen, Denmark. The company has been active for 19 years. It trades publicly under the ticker symbol ASND. As a rare disease specialist, the company dedicates its resources to developing therapies for patients with rare and orphan conditions.